NRSN

NeuroSense Therapeutics (NRSN)

About NeuroSense Therapeutics (NRSN)

Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company, which engages n the discovery and development of targeted therapeutics for neurodegenerative diseases. The firm offers PrimeC, a therapy for amyotrophic lateral sclerosis (ALS). It also conducts testing of product candidates for the treatment of Parkinson's and Alzheimer's diseases. The company was founded by Alon Ben-Noon on February 13, 2017 and is headquartered in Herzliya, Israel.

Details

Daily high
$0.82
Daily low
$0.76
Price at open
$0.82
52 Week High
$2.60
52 Week Low
$0.76
Market cap
24.1M
Dividend yield
0.00%
Volume
1,250
Avg. volume
412,384
P/E ratio
-1.39

NeuroSense Therapeutics News

Details

Daily high
$0.82
Daily low
$0.76
Price at open
$0.82
52 Week High
$2.60
52 Week Low
$0.76
Market cap
24.1M
Dividend yield
0.00%
Volume
1,250
Avg. volume
412,384
P/E ratio
-1.39